TEOSYAL® RHA1

Product Overview: TEOSYAL® RHA 1

TEOSYAL® RHA 1 is an injectable, non-pyrogenic, transparent viscoelastic gel composed of both cross-linked and non-modified resilient hyaluronic acid (RHA) of non-animal origin, incorporating 0.3% lidocaine hydrochloride for patient comfort during treatment. Manufactured by Teoxane Laboratories in Geneva, Switzerland, a leader in hyaluronic acid-based aesthetic products, RHA 1 utilizes patented RHA technology designed to preserve the natural characteristics of HA chains, enabling the gel to better mimic natural hyaluronic acid and adapt to facial dynamics.

This formulation is specifically indicated for the correction of fine lines and superficial wrinkles on the face, neck, and décolleté. It aims to provide subtle correction while maintaining natural facial expression and movement.

Note: This product is intended for use only by licensed medical professionals trained in dermal filler injection techniques.

Mechanism of Action and Properties

TEOSYAL® RHA 1 leverages Resilient Hyaluronic Acid (RHA) technology. This process aims to maintain longer HA chains within a mobile network, allowing the gel to stretch and adapt within the tissues when subjected to facial movement (dynamic strain). Upon injection into the superficial to mid-dermis, the hyaluronic acid component works by augmenting tissue volume and attracting water molecules, thereby hydrating the skin and smoothing the appearance of fine wrinkles.

The inclusion of lidocaine hydrochloride provides local anesthesia, reducing discomfort during the injection procedure.

Clinical outcomes typically show results lasting for several months, though individual patient results may vary based on factors such as skin type, severity of wrinkles, injection area, and technique.

Indications and Usage

TEOSYAL® RHA 1 is indicated for filling fine lines and superficial wrinkles, particularly in mobile areas of the face and neck where natural expression is key. Common treatment areas include:

• Perioral fine lines
• Forehead lines (superficial)
• Crow’s feet (superficial)
• Neck lines
• Décolletage wrinkles

Administration should be performed by qualified practitioners according to standard protocols for dermal filler injection into the appropriate dermal plane.

Expected Outcomes

When used appropriately by a trained professional, TEOSYAL® RHA 1 aims to achieve:

• Smoothing of fine lines and superficial wrinkles
• Improved skin hydration and texture in the treated area
• Maintenance of natural facial expression and movement
• Enhanced skin radiance

Potential Adverse Events

As with any dermal filler injection, patients may experience temporary reactions at the injection site. Practitioners should inform patients about potential adverse events, which may include, but are not limited to:

• Common Reactions: Erythema (redness), swelling, bruising, pain, tenderness, itching, or small lumps/bumps at the injection site. These reactions are typically mild to moderate and resolve within a few days.
• Less Common/Rare but Serious Reactions: Discoloration, induration (hardness), infection, abscess formation, hypersensitivity reactions, nodule formation, granulomas, skin necrosis (rare), or vascular complications (rare).

Practitioners must be prepared to manage potential complications. Patients should be advised to report any persistent or concerning reactions promptly.

Package Contents

• 2 x 1ml prefilled syringes
• 4 x 30G ½´´ needles
• Traceability labels
• Product insert

Storage Conditions

Store between 2°C and 25°C. Protect from freezing and sunlight. Do not use if the package is damaged.

Disclaimer: Practitioners must follow product guidelines for complete prescribing information, including contraindications, warnings, precautions, and potential adverse events, before using TEOSYAL® RHA 1. This information above is not exhaustive.